LAG3 and breast carcinoma: In addition, in 128 breast cancer patients with a defined survival period data, the Kaplan-Meier results showed that immune checkpoints, such as VISTA (VISTA+ compared with VISTA-; p = 0.078), TIGIT (TIGIT+ compared with TIGIT-; p = 0.137), TIM3(TIM3+ compared with TIM3-; p = 0.176), and LAG3 (LAG3+ compared with LAG3-; p = 0.121), were not associated with overall survival.